Phase 3 Clinical Trials With Primary Completion Dates in August 2018
This is a list of Phase 3 trials with primary completion dates in August 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|AIMT||Aimmune Therapeutics, Inc.||2018-08-01||Phase 3||NCT03126227||Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children|
|ALKS||Alkermes plc||2018-08-01||Phase 3||NCT02110264||Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)|
|AQXP||Aquinox Pharmaceuticals, Inc.||2018-08-01||Phase 3||NCT02858453||Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome|
|AVEO||AVEO Pharmaceuticals, Inc.||2018-08-01||Phase 3||NCT02627963||A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC|
|ENDP||Endo International plc||2018-08-01||Phase 3||NCT03446781||Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women|
|ENDP||Endo International plc||2018-08-01||Phase 3||NCT03428750||Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women|
|ESPR||Esperion Therapeutics, Inc.||2018-08-01||Phase 3||NCT02991118||Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk|
|FGEN||FibroGen, Inc||2018-08-01||Phase 3||NCT02964936||A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia|